II. Indications
-
Hypertension
- Weak Diuretic primarily used to counter urinary Potassium loss with other Diuretics
- Typically combined with Thiazide Diuretics (rarely used alone)
III. Contraindications
- Significant Renal Insufficiency
- Anuria
- Hyperkalemia
IV. Mechanism
- Potassium-Sparing Diuretics only (Aldosterone independent)
- Primarily used to counter urinary Potassium loss with other Diuretics (e.g. Thiazide Diuretics)
- Act directly at the distal convoluted tubule (Aldosterone independent)
V. Dosing
- Dose: 100 mg orally twice daily
- Maximum: 300 mg/day
- Typically used as Combination Medication with Thiazide Diuretic
- Diazide (37.5 to 50 mg Triamterene and 25 mg Hydrochlorothiazide)
- Maxide (75 mg Triamterene and 50 mg Hydrochlorothiazide)
VI. Pharmacokinetics
- Rapidly absorbed, highly metabolized in liver and Kidney and rapidly excreted
- Onset: 2 to 4 hours
- Duration: 7 to 9 hours
VII. Adverse Effects
- See Potassium-Sparing Diuretic
- Blue Urine Color
- Specific to Triamterene
VIII. Safety
- Pregnancy Category B
- Avoid in Lactation
IX. Resources
X. References
- (2021) Presc Lett, Resource #370507, Commonly Used Diuretics
- (2020) Med Lett Drugs Ther 62(1598): 73-80
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 62-3
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
triamterene (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP | Generic | $0.12 each |
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB | Generic | $0.09 each |
TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB | Generic | $0.13 each |
Ontology: Triamterene (C0040869)
Definition (MSH) | A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. |
Definition (NCI) | A pteridine derivative with potassium-sparing diuretic property. Triamterene blocks the sodium-potassium exchange pump (Na-K-ATPase) in the luminal membrane of principal cells in the late distal tubule, cortical collecting tubule and collecting duct in the kidney. This reversible inhibition of the electrogenic sodium transport decreases the lumen-negative transepithelial potential difference and thus reduces the driving force for K+ movement into the tubular lumen resulting in the inhibition of sodium reabsorption in exchange for K+ and H+. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D014223 |
SnomedCT | 12512008, 387053007 |
LNC | LP14734-5, MTHU001919 |
English | Triamterene, 2,4,7-Pteridinetriamine, 6-phenyl-, triamterene, triamterene (medication), TRIAMTERENE, Triamterene [Chemical/Ingredient], 6-Phenyl-2,4,7-triaminopteridine, 6-Phenyl-2,4,7-pteridinetriamine, Triamterene (product), Triamterene (substance) |
Swedish | Triamteren |
Czech | triamteren |
Finnish | Triamtereeni |
Russian | TRIAMTEREN, PTEROFEN, ПТЕРОФЕН, ТРИАМТЕРЕН |
Japanese | トリアムテレン |
Polish | Triamteren |
Spanish | triamtereno (producto), triamtereno (sustancia), triamtereno, Triantereno |
French | Triamtérène |
German | Triamteren |
Italian | Triamterene |
Portuguese | Triantereno |
Ontology: Dyrenium (C0700653)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D014223 |
English | Dyrenium, Wellspring Brand of Triamterene |